ECSP055972A - 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas - Google Patents

4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas

Info

Publication number
ECSP055972A
ECSP055972A EC2005005972A ECSP055972A ECSP055972A EC SP055972 A ECSP055972 A EC SP055972A EC 2005005972 A EC2005005972 A EC 2005005972A EC SP055972 A ECSP055972 A EC SP055972A EC SP055972 A ECSP055972 A EC SP055972A
Authority
EC
Ecuador
Prior art keywords
chinoclincarbonitrils
metoxifenil
dicloro
alcoxi
ischemical
Prior art date
Application number
EC2005005972A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Margareth Maria Zaleska
Frank Charles Boschelli
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055972A publication Critical patent/ECSP055972A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la Fórmula (I), en donde X es N, CH; n es un número entero de 1 a 3; y R y R' independientemente son alquilo de 1 a 3 átomos de carbono, y sales farmacéuticamente aceptables de dichos compuestos, con la condición de que cuando n es 1, X no puede ser N; son útiles para la inhibición de la permeabilidad vascular causada por enfermedad, lesión o algún otro trauma.
EC2005005972A 2003-02-21 2005-08-19 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas ECSP055972A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
ECSP055972A true ECSP055972A (es) 2006-01-16

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005972A ECSP055972A (es) 2003-02-21 2005-08-19 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas

Country Status (19)

Country Link
US (1) US20040229880A1 (es)
EP (1) EP1594502A1 (es)
JP (1) JP2006522023A (es)
KR (1) KR20050102133A (es)
CN (1) CN1750824A (es)
AR (1) AR043253A1 (es)
AU (1) AU2004216235A1 (es)
BR (1) BRPI0407441A (es)
CA (1) CA2516418A1 (es)
CO (1) CO5640114A2 (es)
CR (1) CR7931A (es)
EC (1) ECSP055972A (es)
MX (1) MXPA05008706A (es)
NO (1) NO20054070L (es)
RU (1) RU2005129333A (es)
TW (1) TW200423938A (es)
UA (1) UA80472C2 (es)
WO (1) WO2004075898A1 (es)
ZA (1) ZA200506621B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1874776A (zh) 2003-11-06 2006-12-06 惠氏公司 治疗慢性骨髓性白血病(cml)的4－苯胺基－3－喹啉腈
MX2007004833A (es) * 2004-10-22 2007-05-16 Wyeth Corp 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica.
WO2007005462A1 (en) * 2005-07-01 2007-01-11 Wyeth Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same
MX342879B (es) * 2010-07-30 2016-10-14 Oncotherapy Science Inc * Derivados de quinolina e inhibidores de cinasa de cremallera de leucina embrionica materna que los contienen.
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
IN2014CH00840A (es) * 2014-02-20 2015-09-18 Apotex Inc
TWI672141B (zh) 2014-02-20 2019-09-21 美商醫科泰生技 投予ｒｏｓ１突變癌細胞之分子
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
AU2015355220B2 (en) 2014-12-02 2020-02-27 Ignyta, Inc. Combinations for the treatment of neuroblastoma
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
AU2018302170B2 (en) 2017-07-19 2024-02-29 Ignyta, Inc. Pharmaceutical compositions comprising entrectinib
EP3697390A1 (en) 2017-10-17 2020-08-26 Ignyta, Inc. Pharmaceutical compositions and dosage forms
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2500368A1 (en) * 2002-10-04 2004-04-22 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
MXPA05008706A (es) 2005-10-05
KR20050102133A (ko) 2005-10-25
JP2006522023A (ja) 2006-09-28
TW200423938A (en) 2004-11-16
WO2004075898A1 (en) 2004-09-10
CO5640114A2 (es) 2006-05-31
NO20054070L (no) 2005-11-14
NO20054070D0 (no) 2005-09-01
AR043253A1 (es) 2005-07-20
CR7931A (es) 2006-02-07
ZA200506621B (en) 2008-02-27
CA2516418A1 (en) 2004-09-10
EP1594502A1 (en) 2005-11-16
UA80472C2 (en) 2007-09-25
RU2005129333A (ru) 2006-01-27
US20040229880A1 (en) 2004-11-18
CN1750824A (zh) 2006-03-22
AU2004216235A1 (en) 2004-09-10
BRPI0407441A (pt) 2006-01-31

Similar Documents

Publication Publication Date Title
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
ECSP066548A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
UY27918A1 (es) Derivados de benzodioxol
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CR10127A (es) Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CR10376A (es) Derivados de terfenil para el tratamiento de la enfermedad de alzheimer
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
UY27018A1 (es) Derivados de la pirimidina
MX2007011814A (es) Compuestos citoesqueleticos activos, composiciones y usos.
ECSP077385A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesión isquémica
AU8519601A (en) 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
PA8531601A1 (es) Nuevos heteroaromatos
NO20053997L (no) Oligosaccharidderivat
CR6503A (es) Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano
AR037140A1 (es) Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende
ATE413174T1 (de) Nicht-nucleoside revers-transcriptase inhibitoren
IS3887A (is) Lyfjablanda til þess að lækka háan blóðþrýsting, aðferð til framleiðslu hennar og notkunar sem lyfs